植物雌激素在防治心肌缺血再灌注损伤的应用前景  

Phytoestrogens in application prospect of treatment of myocardial ischemia/reperfusion injury

作　　者：李光[1,2] 邢小燕[1] 张美双[1] 石金金[1] 邓雪红[1] 孙桂波[1] 孙晓波[1] 

机构地区：[1]中国医学科学院药用植物研究所,北京100093 [2]中国医学科学院药用植物研究所云南分所,云南景洪666100

出　　处：《中国中药杂志》2015年第16期3132-3136,共5页China Journal of Chinese Materia Medica

基　　金：国家自然科学基金项目(81303257;81374011;81374010);中国博士后科学基金项目(2013M540067;2014T70054)

摘　　要：心肌缺血再灌注损伤是心血管疾病领域研究的热点问题之一,目前临床上尚缺乏有效的防治手段。临床研究发现冠心病的绝经前女性患者要明显低于男性患者,说明雌激素在其发生发展过程中具有一定的作用,使雌激素替代疗法逐渐成为新的防治研究热点。大量植物雌激素应用于心血管疾病的预防治疗研究,以期消除合成类雌激素在治疗中副作用。该文总结了雌激素受体在心肌缺血再灌注损伤中的作用,雌激素替代疗法的应用及局限性,以及植物雌激素在其防治过程中的应用前景,以期为开发安全、有效的新型药物提供思路和参考。Reperfusion is the most effective treatment for acute myocardial infarction, markedly reducing mortality and morbidity. Reperfusion however induces necrotic and apoptotic damages to cardiomyocytes, that were viable prior to reperfusion, a process called myocardial ischemia/reperfusion injury（MI/RI）. Over the past 30 years, hundreds of experimental interventions （both pharmacologic and nonpharmacologic） have been reported to protect the ischemic myocardium in experimental animals; however, with the exception of early reperfusion, none has been translated into clinical practice. The population-based survey assessed men have about twice the total incidence of morbidity and mortality of women, and the sex gap in morbidity tends to diminish after age 45 years. So hormone replace- ment therapy （HRT） is given to treat the MI/RI, and lots of studies shows that the side effect is greater for estrogen, compared with phyestrogen. In this article, we review the important pathogenesis of myocardial ischemia reperfusion injury, the prevention and limita- tions of HRT. And we highlight the mechanism of phyestrogens treatment the MI/RI in experiment. The aim is to provide the theoreti- cally new way of develop the safe and effective products for the researchers.

关 键 词：心肌缺血再灌注损伤 植物雌激素 

分 类 号：R285[医药卫生—中药学]